Crossmark

Combined enzyme/prodrug treatment by genetically engineered AT-MSC exerts synergy and inhibits growth of MDA-MB-231 induced lung metastases

Crossref DOI link: https://doi.org/10.1186/s13046-015-0149-2

Published Online: 2015-04-09

Published Print: 2015-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Matuskova, Miroslava

Kozovska, Zuzana

Toro, Lenka

Durinikova, Erika

Tyciakova, Silvia

Cierna, Zuzana

Bohovic, Roman

Kucerova, Lucia
License Information

License valid from 2015-04-09
More Information

Article History

Received: 3 March 2015

Accepted: 18 March 2015

First Online: 9 April 2015